ROCKAWAY, N.J., October 14, 2024 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the LD Micro Main Event XVII on Tuesday, October 29 at 4:30 p.m.
ROCKAWAY, N.J. , Sept. 26, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor events: October 1 - Management will participate in one-on-one meetings at
ROCKAWAY, N.J. , Sept. 24, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has engaged FNK IR, an institutionally focused investor relations consulting firm, to develop and deploy an expanded outreach
Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training ROCKAWAY, N.J. , Sept. 10, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the
ROCKAWAY, N.J. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the 26 th Annual H.C. Wainwright Global Investment Conference taking place in New York City on
ROCKAWAY, N.J. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s CEO, Dan Goldberger, is scheduled to participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1
Seventh consecutive record quarterly net sales of $6.1 million , an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J. , Aug. 07, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc.
ROCKAWAY, N.J. , Aug. 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on August 1, 2024 , Stephen Smith joined electroCore as the Company’s VP, Quality, Regulatory, and Compliance,
Clinical Trial demonstrates that nVNS is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants ROCKAWAY, N.J. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and
ROCKAWAY, N.J. , July 31, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2024 , after the close of the market on Wednesday, August